Response to safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience
Sign Up to like & getrecommendations! Published in 2018 at "Graefe's Archive for Clinical and Experimental Ophthalmology"
DOI: 10.1007/s00417-018-4095-5
Abstract: Dear Editor, We thank our colleagues Dan Călugăru and Mihai Călugăru for their interest in our paper recently published in this Journal [1]. We thank them for highlighting their contribution to retinal vein occlusion (RVO)… read more here.
Keywords: anti vegf; vegf agents; vein occlusion; treatment ... See more keywords
Intravitreal anti‑VEGF agents and cardiovascular risk: comment
Sign Up to like & getrecommendations! Published in 2020 at "Internal and Emergency Medicine"
DOI: 10.1007/s11739-020-02455-4
Abstract: We read with great interest, the review of intravitreal antivascular endothelial growth factor (VEGF) agents and cardiovascular risk by Porta and Striglia [1]. The authors provide an excellent summary of the research with the agents… read more here.
Keywords: anti vegf; vegf agents; pre injection; post ... See more keywords
Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Gut"
DOI: 10.1136/gutjnl-2019-320116
Abstract: We read with great interest the article by Gerbes et al, 1 which indicated the prospects of immune-based therapies in hepatocellular carcinoma (HCC) and that by Zhu et al, 2 which proposed their new strategy… read more here.
Keywords: hepatocellular carcinoma; combination; vegf agents; hcc ... See more keywords
Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis
Sign Up to like & getrecommendations! Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s383101
Abstract: Abstract Currently, the treatment for ocular neovascular diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. Although it can preserve vision,… read more here.
Keywords: vegf agents; retinal angiogenesis; anti vegf; release strategies ... See more keywords
Anti-VEGF Treatment in Corneal Diseases.
Sign Up to like & getrecommendations! Published in 2020 at "Current drug targets"
DOI: 10.2174/1389450121666200319111710
Abstract: BACKGROUND Corneal neovascularization (CN) is a clue feature of different ocular pathological conditions and can lead to corneal edema and opacification with subsequent vision loss. Vascular endothelial growth factor (VEGF), which plays a key role… read more here.
Keywords: anti vegf; vegf agents; corneal; vegf ... See more keywords
Anti‐VEGF Agents and the Risk of Arteriothrombotic Events
Sign Up to like & getrecommendations! Published in 2018 at "Asia-Pacific Journal of Ophthalmology"
DOI: 10.22608/apo.2017495
Abstract: Abstract: Blockade of vascular endothelial growth factor (VEGF) signaling, whether via sequestration of free VEGF or via inhibition of the tyrosine kinases activated by VEGF, is associated with decreased nitric oxide (NO) and prostaglandin‐I 2… read more here.
Keywords: anti vegf; vegf agents; vegf; arteriothrombotic events ... See more keywords
Does the HFA/ICOS tool overestimate the risk of cardiovascular toxicities in oncologic patients scheduled to receive anti-VEGF agents?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiovascular Medicine"
DOI: 10.2459/jcm.0000000000001346
Abstract: Letter to the Editor TheHeart Failure Association of the European Society of Cardiology (HFA) and the International Cardio-Oncology Society (ICOS) recently proposed the use of a chartbased tool for the baseline cardiovascular risk assessment of… read more here.
Keywords: patients scheduled; vegf agents; oncologic patients; anti vegf ... See more keywords
Anti-VEGF agents for the treatment of diabetic macular edema
Sign Up to like & getrecommendations! Published in 2019 at "Clinical ophthalmology"
DOI: 10.32364/2311-7729-2019-19-4-238-244
Abstract: According to the International Diabetes Federation, in 2017, approximately 425 million adults were living with diabetes. Diabetic retinopathy and diabetic macular edema (DME) are the leading causes of vision loss in the working-age population. They… read more here.
Keywords: diabetic macular; macular edema; treatment; anti vegf ... See more keywords
Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy
Sign Up to like & getrecommendations! Published in 2023 at "Life"
DOI: 10.3390/life13051098
Abstract: Diabetic retinopathy (DR) is a microvascular disease caused by poorly controlled blood glucose, and it is a leading cause of vision loss in people with diabetes. In this review we discuss the current management of… read more here.
Keywords: vegf agents; retinopathy; anti vegf; management ... See more keywords